Afatinib is used for the treatment of certain non-small cell lung cancers, but some populations should avoid it or use it with caution. The following introduces precautions for patients with severe hepatic or renal impairment, pregnant women, and breastfeeding patients.

I. Patients with Severe Hepatic Impairment

1. Risks

Afatinib is mainly metabolized by the liver, and severe hepatic impairment can affect drug clearance.

It may lead to drug accumulation and increase the risk of adverse reactions.

2. What to Know

Patients with severe hepatic impairment should use it with caution or avoid it.

Liver function should be tested regularly before and during treatment.

If jaundice, fatigue, decreased appetite, or dark urine occurs, seek medical attention immediately.

The doctor may adjust the dose or suspend medication based on liver function.

II. Patients with Severe Renal Impairment

1. Risks

Renal impairment can affect drug excretion and increase systemic exposure.

Adverse reactions may be more pronounced in patients with severe renal impairment.

2. What to Know

Patients with severe renal impairment should use it with caution, and the dose should be adjusted if necessary.

Renal function should be monitored regularly during treatment.

Pay attention to diarrhea, dehydration, and other conditions to avoid increasing the burden on the kidneys.

If there is a significant decrease in urine output or edema, seek medical attention promptly.

III. Pregnant Women

1. Risks

Animal studies show that afatinib may harm the fetus.

Use in pregnant women may affect fetal development and may even lead to miscarriage or malformation.

2. What to Know

Afatinib is contraindicated in pregnant women.

Women of childbearing age should use effective contraception during treatment and for a period after discontinuation.

If pregnancy occurs or is suspected during treatment, inform the doctor immediately.

Do not stop or continue the medication on your own; the decision should be made after evaluation by a doctor.

IV. Breastfeeding Patients

1. Risks

It is not yet clear whether afatinib passes into human breast milk.

The drug may cause serious adverse reactions in breastfed infants.

2. What to Know

Afatinib is not recommended for breastfeeding women.

Breastfeeding should be stopped during treatment and for a period after the last dose.

Alternative feeding methods should be discussed with a doctor.

Do not resume breastfeeding on your own; it should be evaluated by a doctor first.